Clinical trial

Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER Study

NCT05220358

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-06-15

PhasePHASE4

Study timeline

Study start (actual)2022-06-15Date precision: day

Registry last updated2025-08-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV-1-infectionunresolved

Interventions

Fostemsavir 600 MG [Rukobia]DRUG

Sponsors & collaborators

Orlando Immunology Centerlead sponsor

ViiV Healthcarecollaborator

Mapped research locations

OrlandoFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05220358 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.